rates \( n = 25 \) (73.5\%) than those with complete pathologic response \( n = 9 \) (26.5\%) \( (p = 0.006) \). Surgery performed until 6 months after CRT reduced recurrences in the first 5 years of follow up \( (p=0.01) \). Among patients submitted to surgery with RD, 89.5\% \( (n = 17/19) \) presented distant metastasis during follow up \( (p=0.03) \). Multivariate analysis showed RD as a predictive factor for recurrence \( (p=0.02, \ HR = 1.85 \ CI \ (1.07–3.19)) \). DFS and OS was not significantly different between surgery and control group (log rank test, \( p = 0.25 \) and \( p = 0.13 \), respectively). In multivariate analysis, overall survival was found to be associated with RD \( (p=0.001) \) and recurrence \( (p<0.001) \).

**Conclusions** Completion surgery after CRT highlights the pathologic response as a prognostic factor. It cannot be accessed with accuracy by physical exam, imaging or biopsy and is associated with recurrence and death bringing information that can be used to tailor further treatment.

**EPV043/#200**

**THE INCREASING INCIDENCE OF METASTATIC CERVICAL CANCER IN THE UNITED STATES – WHAT FACTORS ARE RESPONSIBLE?**

1C-I Liao, 2A Francoeur, 3A Milki, 4E Thayer, 5A Mann, 6MA Caesar, 7A Chan, 8B Monk, 9D Kapp, 10DK chan, 11K Voong. 1Kaohsiung Veterans General Hospital, Obstetrics and Gynecology, Kaohsiung City, Taiwan; 2University of California Los Angeles, Obstetrics and Gynecology, Los Angeles, USA; 3George Washington University School of Medicine and Health Sciences, Obstetrics and Gynecology, Washington DC, USA; 4University of Massachusetts Medical School, Obstetrics and Gynecology, Worcester, USA; 5Palo Alto Medical Foundation, Research Institute, Palo Alto, USA; 6California Pacific Medical Center, Research Institute, San Francisco, USA; 7Palo Alto Medical Foundation Research Institute, Obstetrics and Gynecology, Palo Alto, USA; 8Arizona Oncology, Gynecologic Oncology, Obstetrics and Gynecology, Phoenix, USA; 9Stanford University School of Medicine, Department of Radiation Oncology, Stanford, USA; 10California Pacific Medical Center, Obstetrics and Gynecology, San Francisco, USA

**Objectives** To determine the incidence and trends of advanced stage cervical cancer in the United States. **Methods** Data were obtained from the U.S. Cancer Statistics program from 2001–2017. SEER*Stat 8.3.8 and Joinpoint regression program 4.8.0.1 were used to calculate incidence trends.

Results Of 27,102 patients with advanced stage cervical cancer from 2001–2017, 17,097 (63\%) were White, 4,939 (5\%) were Black, 3,636 were Hispanic (2\%), and 1,117 were Asian (0.5\%). Over time, there has been an annual increase in advanced stage cervical cancer at a rate of nearly 2\% per year \( (p<0.001) \); however, those with early stage cancers have a decrease of 1.54\% annually \( (p<0.001) \). Women aged 30 to 65 years showed an overall increase in incidence, however those 30–34 years olds have a particularly high increase at 3.39\% annually \( (p<0.001) \). Although the overall incidence of advanced cancers is higher in Hispanic and Black populations, there is an increasing number of new cases in White women at 2.39\% annually \( (p<0.001) \). Compared to other groups, the intersection of White women aged 40–44 in the South have the highest average annual increase at 5.07\% \( (p<0.001) \).

**Conclusions** Although the overall incidence of advanced cervical cancers is highest in Hispanic and Black women, there is an increase in incidence in White women particularly in the Southern region of the U.S. More research is needed to understand this trend particularly in relation to screening and treatment of precan-cerous disease.

**EPV044/#201**

**UNDERSTANDING THE NEVER-SCREENED POPULATION FOR CERVICAL CANCER IN THE UNITED STATES – A DESCRIPTIVE AND TREND ANALYSIS**

1A Francoeur, 2C-I Liao, 3D Wong, 4E Thayer, 5A Milki, 6A Moon, 7A Mann, 8MA Caesar, 9A Chan, 10D Kapp, 11B Monk, 12DK chan, 13K Voong. 1University of California Los Angeles, Obstetrics and Gynecology, Los Angeles, USA; 2Kaohsiung Veterans General Hospital, Obstetrics and Gynecology, Kaohsiung City, Taiwan; 3University of California Los Angeles, Obstetrics and Gynecology, Los Angeles, USA; 4George Washington University School of Medicine and Health Sciences, Obstetrics and Gynecology, Washington DC, USA; 5Stanford University School of Medicine, Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford, USA; 6Palo Alto Medical Foundation, Research Institute, Palo Alto, USA; 7California Pacific Medical Center, Research Institute, San Francisco, USA; 8Palo Alto Medical Foundation Research Institute, Obstetrics and Gynecology, Palo Alto, USA; 9Stanford University School of Medicine, Department of Radiation Oncology, Stanford, USA; 10California Pacific Medical Center, Obstetrics and Gynecology, San Francisco, USA

**Objectives** Prior studies have found an increase in advanced stage cervical cancers in the US. We propose to determine the high risk group based on demographic and clinical characteristics.

**Methods** Microscopic confirmed cervical cancer was obtained from United States Cancer Statistics (USCS) from 2001 to 2017. Age-adjusted incidence (AAI, per 100,000 women, corrected by US 2000 standard population), age-specific incidence (ASI, per 100,000 women), and trends were calculated by SEER*Stat 8.3.8 and Joinpoint Regression Program 4.8.0.1.

**Results** Of 27,102 patients with advanced stage cervical cancer from 2001–2017, 17,097 (63\%) were White, 4,939 (5\%) were Black, 3,636 were Hispanic (2\%), and 1,117 were Asian (0.5\%). Squamous and adenocarcinoma consists of 17,867 and 4,992 patients, respectively. The age group with the highest incidence of advanced cancer was 50–54 years, 2,29/100,000. Based on race, Black and Hispanic patients have higher incidence at 1.35/100,000 and 1.18/100,000 compared to White patients, 0.86/100,000. With respect to region, the South has the greatest incidence at 1.04/100,000. The intersectionality of age, race and region finds that Black women, aged 65–69, residing in the South have the highest incidence at 4.19/100,000, an incidence nearly three times higher than White women of the same age in the South at only 1.63/100,000.

**Conclusions** Advanced stage cervical cancer continues to disproportionately affect minorities in Southern regions in the US. Resources toward screening and vaccination are needed in these at risk groups.